Maastricht University Medical Center

Maastricht 10 trials 5 recruiting

10 Registered trials

5 Currently recruiting

Organisation

Maastricht University Medical Center

Location

Maastricht, Netherlands

Identifier

ORL-000001298

Address

P Debyelaan 25, 6229HX, Netherlands

Departments

Cardiology
Gastroenterology
Medical oncology
MMI
Pulmonary Medicine
Radiology and Nuclear Medicine
Surgery

Clinical trials at this site (10)

Search interface

18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study Not authorised

2023-508066-15-00 Hormone-positive breast cancer 4
Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI… Not authorised

2024-514693-47-00 EGFR mutated locally advanced or metastatic non-small c 11
Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting

2022-501893-21-00 Acute myocardial infarction 4 2022-05-03
Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI… Recruiting

2024-514693-47-01 EGFR mutated locally advanced or metastatic non-small c 11 2025-10-28
18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study Recruiting

2023-508066-15-01 Hormone-positive breast cancer 4 2025-09-01
SIMBA Recruiting

2024-514740-82-00 Inflammatory Bowel Disease 6 2025-07-16
Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting

2023-503582-35-00 Staphylococcus aureus bacteremia 6 2023-10-26
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokine… Ended

2023-506818-45-00 Solid tumors that have a high incidence of Homologous R 7 2022-12-13
Induction chemotherapy for locally advanced rectal cancer. Ended

2023-509758-74-00 Locally advanced rectal cancer 4 2021-07-21
THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDE… Ended

2024-516260-29-00 non-metastatic (borderline) resectable pancreatic cance 5 2024-10-10